Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Diagnostics & Research

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, emerging retail healthcare providers, pharmaceutical companies and insurers, commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Revenue projections:

Revenue projections for DGX
Revenue projections for DGX

The projected decline in DGX's revenues compared to last year is expected to make investors cautious. A drop in revenue often has a direct negative effect on the company's bottom line, signaling potential challenges that could undermine investor confidence and reduce overall profitability.

Financial Ratios:

currentRatio 1.179000
forwardPE 16.726503
debtToEquity 82.737000
earningsGrowth 0.155000
revenueGrowth 0.092000
grossMargins 0.332770
operatingMargins 0.141970
trailingEps 9.060000
forwardEps 11.670700

DGX's current ratio is 1.179, signaling that the company has sufficient cash reserves and current assets to cover its short-term debt obligations. This suggests financial stability, as DGX should not face any issues meeting its short-term liabilities with available resources.
With Quest Diagnostics Incorporated's Forward PE in a favorable range, the stock appears reasonably priced compared to its earnings. This suggests that it's not overpriced and there is room for growth, providing an encouraging opportunity for investors seeking future value increases.
DGX's high debt-to-equity ratio indicates a strong reliance on debt, meaning the company is heavily leveraged. This could increase financial risks if cash flow or earnings decline, making it more difficult for DGX to manage its debt obligations.
DGX's forward EPS being higher than its trailing EPS indicates that the company is expected to achieve greater profitability this financial year. This suggests improving earnings and a stronger financial position compared to the previous year's performance.

Price projections:

Price projections for DGX
Price projections for DGX

DGX's price projections have steadily risen over time, pointing to increasing optimism about the company's prospects. This upward revision suggests that analysts expect DGX to continue delivering solid performance in the future.

Insider Transactions:

Insider Transactions for DGX
Insider Transactions for DGX


Quest Diagnostics Incorporated saw 19 transactions in which shares were sold with market price at 187.89810341282896.DGX had 4 buy transactions while market price was at 176.8400001525879 per share.DGX's current price levels are marked by more sells than buys, potentially signaling a price decline. If this trend continues, it may suggest that investors expect the stock to drop further in value.

Recommendation changes over time:

Recommendations trend for DGX
Recommendations trend for DGX


DGX has been receiving a buy bias from analysts, indicating confidence in its investment potential. This could drive more investors to view DGX as a reliable choice for their money, offering a promising avenue for future growth and financial gains.